CarMax, Inc (KMX) Stock Price Today
Aura AI Summary
Key Stats
- $8.12BMarket Cap
- 2,725,186Volume
- Consumer CyclicalSector
- $64.2252W High
- $30.8852W Low
- 49 DaysTypical Hold Time
- $26.63BEnterprise Value
- -Div Yield
- 0% Sell | 100% BuyTrading Activity
Track CarMax, Inc (KMX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CarMax, Inc has traded between a low of $30.88 and a high of $64.22, highlighting its annual price range. Buy and sell CarMax, Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Most Recent News
Defence Therapeutics appoints Sherry Aulin to Board, boosting expertise in finance and biotech.
Defence Therapeutics, a biotech company focused on precision oncology, has appointed Sherry Aulin to its Board of Directors and Audit Committee. Aulin brings over 20 years of finance experience, including a decade as CFO of Xenon Pharmaceuticals, whe...

Ondine Biomedical partners with NHS to prove Steriwave cuts hospital infections and saves costs fast
Ondine Biomedical has partnered with Mela Solutions, whose software is used in 90% of NHS intensive care units, to help hospitals quickly assess the cost-saving impact of its Steriwave antimicrobial treatment. Steriwave uses light to activate a treat...

Ketamine-based alcohol treatment cuts heavy drinking days by 67%, outperforming some existing drugs in analysis
Solvonis Therapeutics reported that its ketamine-based treatment, SVN-001, reduced heavy drinking days by 67% compared to placebo over four months after treatment, based on a phase II trial analysis. This reduction surpasses results seen with naltrex...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.